CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 280.95 AUD 1.02%
Market Cap: 136B AUD
Have any thoughts about
CSL Ltd?
Write Note

CSL Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CSL Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
CSL Ltd
ASX:CSL
Net Issuance of Common Stock
$40m
CAGR 3-Years
-11%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Net Issuance of Common Stock
AU$80.1m
CAGR 3-Years
14%
CAGR 5-Years
56%
CAGR 10-Years
28%
Mesoblast Ltd
ASX:MSB
Net Issuance of Common Stock
$65.4m
CAGR 3-Years
-18%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Net Issuance of Common Stock
-AU$754.2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Net Issuance of Common Stock
AU$6.7m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Net Issuance of Common Stock
AU$92.1m
CAGR 3-Years
31%
CAGR 5-Years
59%
CAGR 10-Years
31%
No Stocks Found

CSL Ltd
Glance View

Market Cap
135.8B AUD
Industry
Biotechnology
Economic Moat
None

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSL Intrinsic Value
235.9 AUD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is CSL Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
40m USD

Based on the financial report for Jun 30, 2024, CSL Ltd's Net Issuance of Common Stock amounts to 40m USD.

What is CSL Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
5%

Over the last year, the Net Issuance of Common Stock growth was 18%. The average annual Net Issuance of Common Stock growth rates for CSL Ltd have been -11% over the past three years , 5% over the past five years .

Back to Top